Recurrent mutations in the gene encoding additional sex combs-like 1 (ASXL1) are found in various hematologic malignancies and associated with poor prognosis. In particular, ASXL1 mutations are common in patients with hematologic malignancies associated with myelodysplasia, including myelodysplastic syndromes (MDSs), and chronic myelomonocytic leukemia. Although loss-of-function ASXL1 mutations promote myeloid transformation, a large subset of ASXL1 mutations is thought to result in stable truncation of ASXL1. Here we demonstrate that C-terminal-truncating Asxl1 mutations (ASXL1-MTs) inhibited myeloid differentiation and induced MDS-like disease in mice. ASXL1-MT mice displayed features of human-associated MDS, including multi-lineage myelodysplasia, pancytopenia, and occasional progression to overt leukemia. ASXL1-MT resulted in derepression of homeobox A9 (Hoxa9) and microRNA-125a (miR-125a) expression through inhibition of polycomb repressive complex 2-mediated (PRC2-mediated) methylation of histone H3K27. miR-125a reduced expression of C-type lectin domain family 5, member a (Clec5a), which is involved in myeloid differentiation. In addition, HOXA9 expression was high in MDS patients with ASXL1-MT, while CLEC5A expression was generally low. Thus, ASXL1-MT-induced MDS-like disease in mice is associated with derepression of Hoxa9 and miR-125a and with Clec5a dysregulation. Our data provide evidence for an axis of MDS pathogenesis that implicates both ASXL1 mutations and miR-125a as therapeutic targets in MDS.
Introduction
Additional sex combs-like 1 (ASXL1) is 1 of 3 mammalian homologs of the Drosophila additional sex combs (Asx), and plays critical roles both in activation and suppression of Hox genes in axial patterning through regulating the polycomb group and trithorax group proteins (1) (2) (3) (4) . ASXL1 is mutated in patients with the entire spectrum of myeloid malignancies including 11%-21% of patients with myelodysplastic syndrome (MDS) (5-8), 10%-15% of patients with myeloproliferative neoplasms (MPNs), 5%-25% of patients with acute myeloid leukemia (AML) (5, 7) , and 43%-58% of patients with chronic myelomonocytic leukemia (CMML) (6, 7, 9, 10) . Additionally, ASXL1 mutations are associated with adverse survival in a variety of myeloid malignancies (8, 9) .
Recently it was reported that ASXL1 binds members of the polycomb repressive complex 2 (PRC2), specifically EZH2, EED, and SUZ12, and that ASXL1 loss in myeloid hematopoietic cells profoundly inhibits trimethylation of histone H3-lysine 27 (H3K27me3), a hallmark repressive modification induced by the PRC2 (11) . ASXL1 also associates with the deubiquitinating enzyme BAP1, which may promote expression of genes (12) through removal of H2A lysine 119 ubiquitination placed by the PRC1 complex. Thus, ASXL1 appears to be involved in both PRC2-mediated gene repression and opposition of PRC1 function (13) .
Although loss of ASXL1 promotes myeloid transformation by impairing PRC2-mediated gene repression at a number of critical loci (11) , intriguingly, most ASXL1 mutations are located in the 5′ region of the last exon (exon 12), which are predicted to result in expression of a truncated ASXL1 protein. As further support for this, ASXL1 mutations are usually heterozygous, leaving 1 allele intact. Therefore, we hypothesized that the C-terminal truncated form of ASXL1 might function as a dominant-negative mutant that suppresses the ASXL1-WT function or alternatively as a gain-of-function mutant (14, 15) . These possible effects of ASXL1 mutations have not been studied and are critical to delineate given the clinical importance of ASXL1 mutations.
In this study we show that ASXL1 mutations profoundly inhibited myeloid differentiation in vitro and induced typical MDS in a mouse model. We then sought to explore the molecular link between ASXL1 mutations and epigenetic disturbances that lead to development of MDS. We identify that expression of mutant forms of ASXL1 results in impaired PRC2 function and impaired myeloid differentiation in vitro and in vivo. Moreover, we identify that ASXL1 mutations induce upregulated expres-sion of microRNA-125a (miR-125a) and subsequent suppression of C-type lectin domain family 5, member a (Clec5a), a type II membrane protein critical for myeloid differentiation. These results identify what we believe is a novel genetically accurate murine model of MDS and additional critical pathways for ASXL1-mediated myeloid transformation. Moreover, these findings suggest therapeutic potential for targeting the mutant forms of ASXL1 as well as miR-125 in the treatment of patients with myeloid malignancies.
Results

Mutant ASXL1 inhibited G-CSF-induced differentiation of 32Dcl3 cells.
Most ASXL1 frame-shift mutations are found in the last exon, which are predicted to result in expression of C-terminal truncated forms. We constructed an N-terminal FLAG-tagged WT ASXL1 (FLAG-ASXL1-WT) as well as N-terminal FLAG-tagged truncated mutants of ASXL1 (FLAG-ASXL1-MT1 and -MT2 ( Figure 1A ). FLAG-ASXL1-MT1 and -MT2 were derived from the mutated genes of 1934dupG;G646WfsX12 and 1900-1922del;E635RfsX15, respectively, of patients with MDS. Although there is some controversy as to whether the most common ASXL1 mutation, 1934dupG;G646WfsX12, represents a true somatic mutation or an artifact (16) , most studies have suggested this allele can occur as a somatic mutation in hematologic malignancies (17) (18) (19) . When transiently expressed in 293T cells or stably expressed in 32Dcl3 cells, these constructs expressed ASXL1-WT and ASXL1 mutant protein (ASXL1-MT) with expected molecular weights detected by an anti-FLAG antibody ( Figure 1B ). As reported previously (11) , immunoprecipitation studies demonstrated that EZH2 bound ASXL1-WT. We further demonstrated that ASXL1-MT as well as ASXL1-WT can bind to EZH2 ( Figure 1C ). ASXL1-WT could also be detected in hemopoietic cell lines by anti-C-terminal ASXL1 antibodies ( Figure 1D) ; HL60, U937, and SET2 harboring only the ASXL1-WT alleles expressed the WT 190-kDa protein. In K562, KU812, and Mono-Mac-6 harboring 1 WT and 1 truncated mutant, ASXL1-WT could be easily detected with the C-terminal antibody. To detect C-terminal truncated endogenous ASXL1 proteins, we used antibodies against the N-terminal part of ASXL1. However, the backgrounds were so high that we could not determine whether the C-terminal-truncated ASXL1 was expressed. Similarly, in TS9;22, KBM-5, and MEG-01 cell lines harboring homozygous truncated ASXL1, we were not able to determine whether the truncated ASXL1 was expressed. We confirmed by quantitative real-time PCR (qRT-PCR) that the ASXL1 transcript was detected in these cell lines (Supplemental Figure 1 ; supplemental material available online with this article; doi:10.1172/JCI70739DS1). When ASXL1-MTs were expressed in 293T cells, they localized to the nucleus ( Figure 1E ) similar to the ASXL1-WT, suggesting that the truncated ASXL1 mutant is expressed and prompting us to examine the effects of stable expression of ASXL1-MTs in both in vitro and in vivo experiments.
We investigated the effects of expression of WT and mutant ASXL1 alleles on hematopoietic differentiation. To this end, we expressed ASXL1-MT1 and -MT2 in 32Dcl3 cells and examined their effect on differentiation of the transduced cells. Interestingly, G-CSFinduced differentiation of 32Dcl3 cells was partially inhibited by the expression of ASXL1-MT1 and -MT2 but not by the expression of ASXL1-WT, based on morphology and flow cytometric expression of CD11b ( Figure 1F ). In addition, all-trans retinoic acid-induced (ATRA-induced) granulocytic differentiation of HL60 and GM-CSFinduced monocytic differentiation of FDC-P1 cells were attenuated by the overexpression of ASXL1-MT2 (Supplemental Figure 2A) . The expression of ASXL1-MTs as well as ASXL1-WT did not affect the growth rate of 32D cells cultured in the presence of IL-3 and did not induce factor-independent growth (Supplemental Figure 2B) . For further experiments, we mainly used ASXL1-MT2 unless otherwise specified, and refer to this mutant hereafter as ASXL1-MT.
ASXL1-MT reduced the expression of Clec5a/Mdl1. To elucidate the molecular mechanisms by which ASXL1-MT inhibited the G-CSFinduced differentiation of 32Dcl3 cells, we compared the expression profiles of parental 32Dcl3 cells and 32Dcl3 cells expressing ASXL1-MT maintained in the presence of 1 ng/ml IL-3 or 50 ng/ml G-CSF. We identified a small set of genes whose expression levels changed more than 2-fold. These included Clec5a/Mdl1, Cd14, and Prom1. Expression of these genes was downregulated in 32Dcl3 cells expressing the ASXL1-MT. Among them, we focused on the type II transmembrane receptor Clec5a (20) , because it was known that Clec5a expression is associated with granulocytic differentiation of 32Dcl3 cells (21) . We confirmed that expression of Clec5a was reduced in 32Dcl3-expressing ASXL1-MT (Figure 2A) . Moreover, while the expression of Clec5a in 32D cells was increased by G-CSF stimulation in a time-dependent manner, as previously reported (21) , both in mRNA and protein levels, this increase was profoundly suppressed by the expression of ASXL1-MT but not by ASXL1-WT ( Figure 2, A and B) . This may result from the observation that myeloid differentiation of 32Dcl3 cells was inhibited by ASXL1-MT, and expression of Clec5a increases with myeloid differentiation, suggesting Clec5a serves as a marker of myeloid differentiation. On the other hand, ATRA or G-CSF-induced granulocytic differentiation of HL60 cells or 32Dcl3 cells, respectively, was enhanced by the expression of Clec5a ( Figure 2C and Supplemental Figure 3A ), suggesting that Clec5a plays a direct role in the differentiation of myeloid cells.
To examine the direct involvement of Clec5a in G-CSF-induced differentiation of 32Dcl3 cells, we designed 2 shRNAs (sh3 and sh4) for Clec5a, which efficiently knocked down Clec5a expression in 32Dcl3 cells (Supplemental Figure 3, B and C) . Intriguingly, G-CSF-induced differentiation of 32Dcl3 was significantly inhibited by Clec5a knockdown (Figure 2D ), suggesting that ASX-L1-MT inhibits differentiation of 32Dcl3 cells, at least in part through suppression of Clec5a. Importantly, ectopic expression of Clec5a in ASXL1-MT-expressing 32Dcl3 cells restored the differentiation ability of 32Dcl3, although this restoration was not induced by a mutant Clec5a that harbors a K16A mutation in the transmembrane domain, which disrupts the ability to associate with DAP12 (data not shown), an activating adaptor for Clec5a that transmits the positive signal associating with Clec5a ( Figure 3 , A and B, Supplemental Figure 3D , and ref. 20) . Thus, ASXL1-MT reduced the expression of Clec5a, which contributes to granulocytic differentiation of 32Dcl3 cells, leading to the disturbed differentiation of 32Dcl3 cells. Interestingly, expression of CLEC5A was reduced in the whole BM cells of the majority of patients with MDS when compared with normal BM cells ( Figure 3C ). However, the presence or absence of ASXL1 mutations did not correlate with CLEC5A expression in BM cells of MDS patients, suggesting that other MDS disease alleles can alter CLEC5A expression in patients with ASXL1-WT.
ASXL1-MTs induced MDS-like disease in mice.
Using a mouse BM transplant (BMT) model, we next examined the in vivo effect of ASXL1-MT expression. BM cells derived from 5-fluorouracil-treated Ly5.2 mice were transduced with a retrovirus vector pMXs-FLAG-ASXL1-MT2-IG (IRES-GFP), and the transduced cells were transplanted into sublethally irradiated Ly5.1 mice. In the transplanted mice, the percentage of the GFP-positive cells gradually increased in the peripheral blood and reached 41%-100% one year after transplantation, while it gradually decreased over time in the mice transplanted with ASXL1-WT-or empty vectortransduced BM cells ( Figure 4A ). GFP-positive cells in the BM of ASXL1-MT-transduced mice 6 months after the transplantation were mostly CD11b positive and included relatively few B220-positive cells, while GFP-negative, nontransduced cells consisted of equal numbers of CD11b-positive and B220-positive cells ( Figure 4B ). All of the transplanted mice displayed more or less morphological abnormalities 12 months or more after transplantation, mainly in myeloid cells and red blood cells ( Figure 4C ), including Pelger-Huet anomaly and hypersegmentation for myeloid cells and Howel-Jolly bodies, polychromasia, and anisopoikilocytosis for erythrocytes, consistent with multi-lineage dysplasia of human MDS. Mice expressing ASXL1-MT died of MDS after a long latency (median survival, 400.5 days), while most of the mock-transduced mice survived nearly 2 years without developing myeloid malignancies ( Figure 4D ). The GFP-positive BM cells that increased in ASXL1-MT-transduced mice were positive for CD11b and weakly positive for Gr1 and CD34. Expression of c-kit varied from positive to negative. These data suggest that a GFP-positive population contains immature and mature myeloid cells ( Figure  4E ). These mice developed severe anemia, leukopenia, and thrombocytopenia, while the BM was hypercellular and the spleen was enlarged (Figure 4 , F and G). Thus, ASXL1-MT-transduced MDS mice developed pancytopenia with dysplasia in granulocytes and erythroid cells and occasionally progressed to overt leukemia, displaying all the features of human MDS. Overexpression of ASXL1-MT1 in the same BMT model revealed basically identical results (Supplemental Figure 4) .
Expression profiles of hemopoietic cells of the mice that developed MDS.
To elucidate the molecular mechanisms by which ASXL1-MT induced MDS, we performed expression profiles of BM cells of mice that developed MDS. We used CD3 -B220 -Ter119 -BM cells of mock-transduced mice as a control. Gene set enrichment analysis (GSEA) indicated that ASXL1-MT induced an expression profile that inversely correlated with known PRC target genes (22) , suggesting that ASXL1-MT inhibited PRC ( Figure 5A ). We also examined the expression of Hoxa genes and Clec5a in BM cells of the mice that developed MDS or MDS/AML after transplantation of ASXL1-MT-transduced BM cells; the expression of posterior Hoxa genes was increased and that of Clec5a was decreased in BM cells of MDS or MDS/AML mice when compared with BM cells of mock-transduced mice ( Figure 5B ). We next performed ChIP of the promoter regions of posterior Hoxa genes using H3K27me3 antibodies and found that H3K27me3 was greatly decreased around the promoter regions of Hoxa5, Hoxa9, and Hoxa10 in the MDS mice, correlating well with the upregulation of their mRNA expression ( Figure 5 , B and C). In addition, Western blot analysis of purified histones in 32Dcl3 cells transduced with ASXL1-MT indicated that H3K27me3 was reduced globally ( Figure 5D ).
Interestingly, HOXA9 expression was increased in whole BM cells of most MDS patients harboring ASXL1 mutations, while the changes in HOXA9 expression was not significant in MDS patients without ASXL1 mutations ( Figure 5E ).
ASXL1-MT collaborated with N-Ras-G12V in inducing leukemia. ASXL1 knockdown reduces the latency and increases the severity miR-125a is responsible for the repression of Clec5a by ASXL1-MT. As shown in Figure 5D , H3K27me3, a transcriptionally repressive mark, was globally reduced by ASXL1-MT. In order to ascertain whether a miRNA involved in myeloid transformation might be upregulated with ASXL1 mutations, we performed microarray analysis of miRNAs in ASXL1-MT-transduced BM cells and mock-transduced BM cells of the BMT model. We identified increased expression of several miRNAs in BM cells expressing ASXL1-MT, including miR-671, miR-125a, miR-714, miR-18b, miR-129, and miR-3107 (Supplemental Table 1 ). Among these, miR-125a is known to regulate hematopoietic stem cell numbers and induce MPN in a mouse BMT model (4, 24) . A closely related miRNA, miR-125b, induces a variety of hematologic malignancies in transgenic mice and BMT models (25) (26) (27) . We confirmed that expression of miR-125a was increased in 32Dcl3 cells expressing ASXL1-MT when compared with those expressing ASXL1-WT or the empty vector (Supplemental Figure 5) . We next evaluated whether Clec5a is a target gene of miR125a. We identified a recognition site of miR-125a in the 3′ untranslated region (3′UTR) of mouse Clec5a and 2 recognition sites in the 3′UTR of human CLEC5A ( Figure 7A ). Therefore, we focused on Mus musculus miR-125a (mmu-miR-125a) and further investigated the effects of miR-125a expression.
First, to confirm that the 3′UTR of the murine Clec5a gene was targeted by miR-125a, we generated an EF1α promoter-driven luciferase construct harboring the 3′UTR of the Clec5a gene ( Figure 7B ) and performed a luciferase assay. As expected, the presence of the 3′UTR of the Clec5a gene reduced luciferase activity ( Figure 7C ). This reduction was completely cancelled by mutating the miR-125a target sequence in the 3′UTR of the Clec5a gene ( Figure 7 , B and C). miR-125b1 and miR-125b2 are genes distinct from miR-125a, but their seed sequence is identical with that of miR-125a. When miR-125a or miR-125b was expressed in 32Dcl3 cells, Clec5a expression was reduced both at mRNA levels and surface expression levels ( Figure 7 , D and E) compared with 32Dcl3 cells transduced with empty vector. Moreover, these cells became more resistant to G-CSF-induced differentiation ( Figure 7F) . These results clearly demonstrate that miR-125a targets Clec5a expression, leading to the inhibition of differentiation.
We next examined H3K27me3 near the transcription start site (TSS) of miR-125a in 32Dcl3 cells transduced with the empty vector, ASXL1-MT, or ASXL1-WT. This revealed profound reduction of H3K27me3 near the TSS of miR-125a in 32Dcl3 cells expressing ASXL1-MT (Figure 8, A-C) . Moreover, H3K27me3 near the TSS of miR-125a was also reduced in BM cells of the mice that developed MDS after the transplantation of the ASXL1-MT-transduced BM cells, when compared with cells from mice engrafted with control BM cells (Figure 8 , A, D, and E). Intriguingly, EZH2 binding to the miR-125a locus was reduced in ASXL1-MT-expressing 32Dcl3 cells or in ASXL1-MT-transduced BM cells from mice that developed MDS, while ASXL1-WT seemed to increase EZH2 binding to the miR-125a locus (Figure 8, B and D) . Altogether, these results indicated a scenario in which ASXL1-MT hampered EZH2 binding to the miR-125a locus and suppressed EZH2-mediated H3K27me3 near the TSS of the miR-125a gene, leading to derepression of miR-125a. The increased miR-125a expression inhibited the expression of Clec5a, contributing to the impaired differentiation of mouse BM cells that developed MDS.
Discussion
We have established and characterized a mouse MDS model induced by ASXL1 mutations. Although MDS patients frequently harbor multiple somatic mutations, it is not clear whether combinations of multiple mutations are required for the development of MDS. In addition, the molecular mechanisms of MDS pathogenesis remain elusive, particularly for recently identified mutations in epigenetic factors. Here we demonstrate that expression of the ASXL1-MT alone induces MDS in the mouse BMT model after a long latency, indicating that ASXL1-MT is a driver mutation in MDS development. Mutations in ASXL1 have been reported in patients with the entire spectrum of myeloid malignancies and are recurrently associated with adverse overall survival, independent of conventional clinical predictors (8, 28) ; this highlights a critical need to understand the precise mechanism of transformation by ASXL1 mutations. Recently, it was indicated that a subset of ASXL1 mutations result in loss of stable expression of full-length ASXL1 of H3K27me3, impaired myeloid differentiation and collaborated with co-occurring genetic alterations, as was seen with downregulation of ASXL1-WT. The observation that expression of ASXL1-MT mirrors the effects of downregulation of ASXL1-WT strongly suggests that in addition to known loss-of-function mutations, a subset of ASXL1 mutations confer dominant-negative activity.
Expression of ASXL1-MT as demonstrated here resulted in impaired myeloid differentiation in vitro and in vivo. ASXL1
and that depletion of ASXL1 promoted myeloid transformation through impaired PRC2-mediated H3K27 methylation (11) .
ASXL1 mutations mostly occur as heterozygous mutations, and the mutations conspicuously occur as nonsense and frameshift mutations in the last exon, prior to the PHD domain. This suggests that most ASXL1 mutations result in a stable protein product that may have gain-of-function mutations. Here we identify that stable expression of ASXL1-MT, which results in global downregulation has been recently reported that disruption of the ASXL1-interacting molecule BAP1 in mice induced CMML-like disease (30) . BAP1 mutation was also identified in a patient with MDS, implicating the BAP1-ASXL1 axis in suppressing MDS. The contribution of disruption of the ASXL1-BAP1 axis (PRC1 related), versus loss of H3K27 trimethylation (PRC2 related), in promoting myeloid transformation induced by ASXL1-MT requires further evaluation.
To understand the transcriptional events responsible for the biological effects of ASXL1 mutations in more detail, we performed transcriptomic studies in the presence of mutant ASXL1 in vitro and in vivo. In addition to identifying significant upregulation of posterior Hoxa genes, we identified increased expression of miR-125a due to locus-specific downregulation of H3K27 methylation. Moreover, it has been reported that miR-125a is upregulated after inhibition of EZH2 by knockdown mutations are most frequent in patients with MDS, MDS/MPN overlap syndromes, and AML with myelodysplasia-related changes, highlighting a close relationship between impaired myeloid differentiation and ASXL1 mutations (29) . We identified that expression of ASXL1-MT in vivo results in the development of a lethal disorder characterized by morphologic dysplasia, leukopenia, and impaired myeloid differentiation with subsequent transformation to AML in some cases, all hallmarks of human MDS. Moreover, co-expression of mutant forms of ASXL1 with oncogenic N-RAS, a complex genotype common to patients with CMML (10), results in a lethal myeloid malignancy with shorter latency than that seen with oncogenic N-RAS alone. Given the paucity of genetically accurate murine models of MDS, expression of ASXL1-MT as demonstrated here may be quite valuable for further mechanistic and preclinical studies of MDS and AML with myelodysplasia-related changes. Interestingly, it 
Methods
Mice. C57BL/6 (Ly5.1) mice (Sankyo Labo Service Corporation) and C57BL/6 (Ly5.2) mice (Charles River Laboratories Japan) were used for BMT experiments.
Cell culture. HEK293T cells were cultured in DMEM supplemented with 10% FBS. Human leukemia cell lines were cultured in RPMI-1640 supplemented with 10% FBS (HL60, U937, K562, KU812, TS9;22, and MEG-01 cells), RPMI-1640 supplemented with 20% FBS (SET2, NOMO1, and MonoMac-6 cells), RPMI-1640 medium supplemented with 10% FBS/1 μM hydrocortisone/10% horse serum (UKE1 cells) or IMDM with 20% FBS (KBM5 cells). The murine myeloid cell lines 32Dcl3 and FDC-P1 were grown in RPMI-1640 medium supplemented with 10% FBS, antibiotics, l-glutamine, and 1 ng/ml IL-3. Before the assays for proliferation and differentiation, the transduced 32Dcl3, HL60, or FDC-P1 cells were GFP sorted or subjected to drug selection with 1 μg/ml puromycin and/or 10 μg/ml blasticidin, if necessary.
Vector construction. We used the retrovirus vectors pMYs-FLAG-ASX-L1-WT-IG and pMYs-FLAG-ASXL1-MT-IG, in which ASXL1-WT or ASXL1-MT (1934dupG;G646WfsX12 or 1900-1922del;E635RfsX15, respectively), tagged with a FLAG epitope at the N terminus, was inserted upstream of the IRES-EGFP cassette of pMYs-IG (39) . Similarly, WT Clec5a or Clec5a-K16A was inserted upstream of the IRES-puro to generate pMYsClec5a-IP or pMYs-Clec5a-K16A-IP. ASXL1-MT was subcloned upstream of the IRES-blasticidin cassette of pMYs-IB. Likewise, Myc-tagged EZH2 was subcloned into pMYs-IG to generate pMYs-Myc-tagged EZH2-IG. To perform the mouse BMT model, we constructed pMYs-N-Ras-G12V-IG and pMYs-ASXL1-MT-IRES-nerve growth factor receptor (pMYs-ASXL1-MT-IRES-NGFR). For knockdown assays, shRNA expression fragments were cloned into pMXs-U6-GFP or pMXs-U6-Puro, which were pMXs-based, self-inactivating retrovirus vectors expressing shRNA under a U6 promoter with a PGK promoter-driven GFP or puromycin-resistant gene expression. An shRNA expression cassette was constructed in the opposite direction from a GFP/Puro expression cassette. We also constructed microRNA vectors as described previously (26) . Briefly, miRNA expression fragments were cloned into pMXs-EF1-Puro vector.
Transfection and retrovirus production. Retroviral production was done as described previously (40) . Briefly, retroviruses were generated by transient transfection of Plat-E packaging cells with using the calcium-phosphate coprecipitation method. Cell lines such as 32Dcl3 were infected with the retroviruses as previously described (39) .
Mutation analysis of ASXL1. Somatic mutations of ASXL1 genes were searched by sequencing exons after PCR amplification of genomic DNA, as described previously (6) .
qRT-PCR. Total RNAs were treated with deoxyribonuclease I (Invitrogen) and reverse transcribed by using High Capacity cDNA Reverse Transcription Kits (Applied Biosystems) or miScript Reverse Transcription Kit (QIAGEN). qRT-PCR was performed using a Rotor-Gene Q (QIAGEN). For mRNA RT-PCR, a SYBR Premix EX Taq (Takara) was used as previously described (41) . Mature miR-125a expression was measured using a miScript SYBR Green PCR kit (QIAGEN). cDNA was amplified with miR125a-specific primers (QIAGEN). Expression of RNA, U6 small nuclear 2 (RNU6B) as an internal control was used for normalization of the results. All data with error bars indicate the mean ± SEM.
Mouse BMT. Mouse BMT was performed as described previously (40) . Briefly, BM mononuclear cells were isolated from the femurs and tibias of C57BL/6 (Ly-5.1) donor mice 3 days after intraperitoneal administration of 150 mg/kg 5-fluorouracil. The cells were stimulated with 50 ng/ml of mouse stem cell factor, mouse FLT3 ligand, mouse IL-6, and human thrombopoietin (all cytokines were from R&D Systems). The prestimulated cells were infected for 60 hours with the retroviruses harboring in DU145 prostate cancer cells (31) . miR-125a was the only miR upregulated in both our murine system and in primary human MDS samples (32) . miR-125a belongs to the miRNA family that also includes miR-125b1 and miR-125b2, all of which have the same seed sequence and have been implicated in human leukemia/lymphoma (33) (34) (35) as well as in MDS (32) . Forced expression of these miRs has been previously shown to induce the expansion of hemopoietic stem cells or hamper myeloid differentiation (4, 24-26, 32, 35) .
Although several proapoptotic genes have been implicated for hematopoietic transformation as miR-125a targets (4, 26, 36) , here we identified direct repression of a novel target Clec5a by miR-125a as a specific effector of the differentiation phenotype. The type II membrane protein CLEC5A (20) belongs to the lectin family and associates with the adaptor protein DAP12 to transmit positive signals. It was previously recognized that Clec5a expression is correlated with myeloid differentiation, as Clec5a is expressed in monocytes and neutrophils, and its expression is increased by granulocytic differentiation of 32Dcl3 cells (21) and monocytic differentiation of U937 cells and primary progenitor cells (37) . Here we present clear evidence that Clec5a supports myeloid differentiation. First, ASXL1-MT but not ASXL1-WT reduced expression of Clec5a in 32Dcl3 cells and impaired G-CSF-induced granulocytic differentiation. Second, in 32D3 cells expressing ASXL1-MT, myeloid differentiation was partly restored by the forced expression of Clec5a, but not by a mutant Clec5a (Clec5a-K16A) that cannot associate with DAP12. Third, knockdown of Clec5a impaired G-CSF-induced differentiation of 32Dcl3 cells. In addition, Clec5a expression was downregulated in the ASXL1-MT-induced MDS mice. These results indicate that downregulation of Clec5a by ASXL1-MT impairs myeloid differentiation and is involved in MDS development. Interestingly, while HOXA9 expression was high in MDS patients with ASXL1 mutations (Figure 5E ), the expression level of CLEC5A was generally low in MDS patients compared with controls and did not correlate with the presence of ASXL1 mutations ( Figure 3C ). This suggests that CLEC5A expression is reduced in MDS by multiple causes including ASXL1 mutations, and that reduction of CLEC5A might play a general role in the pathogenesis of MDS. Prior data indicating downregulation of CLEC5A expression in acute leukemia likewise support the possibility that CLEC5A downregulation may be important in the pathogenesis of multiple subtypes of myeloid malignancies (38) .
The data presented here indicate that ASXL1 mutations, which result in a truncated protein product, may (a) inhibit PRC2 function in a dominant-negative fashion and (b) promote myeloid transformation through impaired PRC2-mediated repression of posterior HOXAs and miR-125a and subsequent miR-125a suppression of CLEC5A. Thus, although changes in expression of other genes caused by ASXL1 mutations may also be involved, it is documented that the derepression of HOXAs and miR-125a and the suppression of CLEC5A contribute to the development of MDS. Given the clinical importance of ASXL1 mutations, the identification of gain-of-function ASXL1 mutations is critical, as it provides a rationale for therapies aimed at targeting the expressed mutant forms of ASXL1. Finally, the data here provide further basis for the involvement of miR-125 in myeloid malignancy pathogenesis and identify an important role for CLEC5A in the pathogenesis of multiple genetic subtypes of myeloid malignancies.
Differentiation assay. The 32Dcl3 cells were induced to differentiate to granulocytes by removing IL-3, washing them twice in RPMI medium without IL-3, and adding G-CSF (R & D Systems) to a final concentration of 50 ng/ml. Cells were cytocentrifuged (Cytospin4; Thermo Shandon), and cell morphologies were evaluated by Giemsa staining 3 or 6 days after G-CSF addition (46) . FDC-P1 cells were washed in RPMI medium and then incubated in murine GM-CSF (10 ng/ml) for 6 days (47). HL60 cells were incubated in the medium supplemented with 10 -6 M ATRA for 3 days. Images were obtained with a BX51 microscope and a DP12 camera (Olympus) with an Olympus UplanFl objective lens. All data with error bars indicate the mean ± SEM. Data are representative of 3 independent experiments.
Luciferase assay. Luciferase assays to investigate whether miRNA binds to the expected target sequence were performed as described previously (26) . All data with error bars indicate the mean ± SEM.
Microarray data. Microarray data have been deposited in Gene Expression Omnibus (accession no. GSE49117 and GSE49118; http://www.ncbi.nlm.nih.gov/geo/).
Statistics. Statistical significance was calculated using the indicated tests for independent variables. All calculations were carried out using the program JMP 8.0 (SAS Institute Inc.). P values of less than 0.05 were considered significant using the 2-tailed Student's t test, unless otherwise noted. In box and whisker plots, the bottom and top of the box indicate the first and third quartiles, and the band inside the box is the second quartile (the median). The lowest or highest datum shows the minimum or maximum of all of data within 1.5 interquartile range of the lower or upper quartile.
Study approval. All animal studies were approved by the Animal Care Committee of the Institute of Medical Science at the University of Tokyo. MDS patients were diagnosed at Hannover Medical School. Diagnosis was based on the World Health Organization classification. Informed consent was obtained in accordance with the Declaration of Helsinki, and the studies were approved by the institutional review board of Hannover Medical School (ethical vote no. 5558) and by the ethics committees of the University of Tokyo (approval 20-10).
